Adam C Olson1,1, Samantha Thomas2,2, Rosie Qin3,3, Bhavana Singh4,4, Joseph K Salama1,1, John Kirkpatrick1,1, April Ks Salama5,5. 1. Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA. 2. Department of Biostatistics, Duke Cancer Institute, Durham, NC, USA. 3. Duke University School of Medicine, Durham, NC, USA. 4. Department of Medicine, Duke University Medical Center, Durham, NC, USA. 5. Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
Abstract
PURPOSE: Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety. METHODS: Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival. RESULTS: We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis. CONCLUSION: SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.
PURPOSE: Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety. METHODS: Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival. RESULTS: We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis. CONCLUSION: SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.
Authors: Stephanie Du Four; Sofie Wilgenhof; Johnny Duerinck; Alex Michotte; Anne Van Binst; Mark De Ridder; Bart Neyns Journal: Eur J Cancer Date: 2012-06-22 Impact factor: 9.162
Authors: Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: Donald N Liew; Hideyuki Kano; Douglas Kondziolka; David Mathieu; Ajay Niranjan; John C Flickinger; John M Kirkwood; Ahmad Tarhini; Stergios Moschos; L Dade Lunsford Journal: J Neurosurg Date: 2010-06-04 Impact factor: 5.115
Authors: John P Kirkpatrick; Zhiheng Wang; John H Sampson; Frances McSherry; James E Herndon; Karen J Allen; Eileen Duffy; Jenny K Hoang; Zheng Chang; David S Yoo; Chris R Kelsey; Fang-Fang Yin Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-21 Impact factor: 7.038
Authors: Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord Journal: J Immunol Date: 2005-06-15 Impact factor: 5.422
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Maya Mathew; Moses Tam; Patrick A Ott; Anna C Pavlick; Stephen C Rush; Bernadine R Donahue; John G Golfinos; Erik C Parker; Paul P Huang; Ashwatha Narayana Journal: Melanoma Res Date: 2013-06 Impact factor: 3.599
Authors: May N Tsao; Dirk Rades; Andrew Wirth; Simon S Lo; Brita L Danielson; Laurie E Gaspar; Paul W Sperduto; Michael A Vogelbaum; Jeffrey D Radawski; Jian Z Wang; Michael T Gillin; Najeeb Mohideen; Carol A Hahn; Eric L Chang Journal: Pract Radiat Oncol Date: 2012-01-30
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Mark P van Opijnen; Linda Dirven; Ida E M Coremans; Martin J B Taphoorn; Ellen H W Kapiteijn Journal: Int J Cancer Date: 2019-11-23 Impact factor: 7.396